Clinical Study
Vinorelbine with or without Trastuzumab in Metastatic Breast Cancer: A Retrospective Single Institution Series
Table 3
Clinical response rates of patients with metastatic breast cancer treated with vinorelbine either as monotherapy or with trastuzumab.
| ||||||||||||||||||||||||||||||||||||||||
CR: complete response, PR: partial response, SD: stable disease, PD: progressive disease, VNR mono: vinorelbine monotherapy, VNR + TRZ: vinorelbine and trastuzumab, and 95% CI: 95% confidence interval. |